Key facts
- It has raised $2.9M; the latest was Seed Round ($2.9M) in Nov 2025.
- Notable investors include DeepTech Capital Consortium, Rubicon Partners (Warsaw), StartSmart CEE, University of Gdansk, iif.vc.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Vaxican
- ·The full record, as it builds
Funding rounds
No funding rounds for Vaxican are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vaxican
Developer of immunotherapy technology designed to improve cancer survival rate. The company offers research and development services, and a novel platform for cancer-vaccine delivery systems to provide the safest and improved way to instruct and boost patients' anti-cell defense forces, enabling customers to have improved access to treatments.
- Sector
- Healthcare
- HQ
- Gdańsk, Poland
- Founded
- 2019
- Employees
- 3
- Website
- vaxican.com/
- Ownership
- Privately Held (backing)
Vaxican doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vaxican shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vaxican in its N-PORT filings yet. We sweep new filings monthly.